Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Is it time to reconsider the treatment paradigm for obese patients with hypertension?

The recent STEP trials reported blood pressure reductions for obese patients treated with semaglutide. We analyzed a cohort of patients attending our hypertension clinic and found that 26% were severely or morbidly obese and morbidly obese patients frequently had resistant hypertension (41%). We suggest semaglutide may be an effective anti-hypertensive agent for obese patients with resistant hypertension and this hypothesis should be assessed in randomized clinical trials.

This is a preview of subscription content

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Fig. 1

References

  1. Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: the STEP 4 Randomized Clinical Trial. JAMA. 2021;325:1414–25.

    CAS  Article  Google Scholar 

  2. Kennedy C, Farnan R, Stinson J, Hall M, Hemeryck L, O’Connor P, et al. Referrals to, and characteristics of patients attending a specialist hypertension clinic. J Hum Hypertens. 2021;Mar 8:1–10.

  3. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021–104.

  4. Irish Heart Foundation, Cardiovascular Disease. https://irishheart.ie/heart-and-stroke-conditions-a-z/cardiovascular-disease/#section-definition. Accessed 10/04/2021.

  5. Gorostegi-Anduaga I, Corres P, MartinezAguirre-Betolaza A, Pérez-Asenjo J, Aispuru GR, Fryer SM, et al. Effects of different aerobic exercise programmes with nutritional intervention in sedentary adults with overweight/obesity and hypertension: EXERDIET-HTA study. Eur J Preventive Cardiol. 2018;25:343–53.

    Article  Google Scholar 

  6. Heymsfield SB, Wadden TA. Mechanisms, pathophysiology, and management of obesity. N Engl J Med. 2017;376:254–66.

    CAS  Article  Google Scholar 

  7. Lakkis JI, Weir MR. Obesity and Kidney Disease. Prog Cardiovasc Dis. 2018;61:157–67.

    Article  Google Scholar 

  8. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384:989–1002.

    CAS  Article  Google Scholar 

  9. Kario K, Ferdinand KC, O’Keefe JH. Control of 24-hour blood pressure with SGLT2 inhibitors to prevent cardiovascular disease. Prog Cardiovasc Dis. 2020;63:249–62.

    Article  Google Scholar 

  10. Lee PC, Ganguly S, Goh SY. Weight loss associated with sodium-glucose cotransporter-2 inhibition: a review of evidence and underlying mechanisms. Obes Rev. 2018;19:1630–41.

    CAS  Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Contributions

CK was responsible for study concept and design, data acquisition, interpretation and analysis, drafting of the paper and final approval. RF was responsible for study concept and design, data acquisition and analysis, drafting of the paper and final approval. JS was responsible for study concept and design, data acquisition and interpretation, critical revision of the paper and final approval. POC, M Hall, M Hennessy and MB were responsible for study supervision, data acquisition and interpretation, critical review of the paper and final approval.

Corresponding author

Correspondence to Cormac Kennedy.

Ethics declarations

Competing interests

The authors report no relationships that could be construed as a competing interests. JS is a clinical specialist at the clinic while also working in pharmaceutical industry. His employer does not manufacture anti-hypertensive medications.

Ethics approval

Ethical approval was granted by the Tallaght Hospital Research Ethics Committee.

Informed consent

Informed consent was sought and provided by all study participants.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kennedy, C., Ali, O., Farnan, R. et al. Is it time to reconsider the treatment paradigm for obese patients with hypertension?. J Hum Hypertens 36, 482–484 (2022). https://doi.org/10.1038/s41371-021-00630-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41371-021-00630-4

Search

Quick links